Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial.

被引：0

作者：

Bellmunt, Joaquim

Aragon-Ching, Jeanny B.

Climent, Miguel Angel

Sridhar, Srikala S.

Powles, Thomas

Cislo, Paul

Michelon, Elisabete

Di Pietro, Alessandra

Grivas, Petros

机构：

[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Inova Schar Canc Inst, Fairfax, VA USA

[3] Inst Valenciano Oncol, Valencia, Spain

[4] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada

[5] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England

[6] Pfizer, New York, NY USA

[7] Pfizer Inc, Milan, Italy

[8] Univ Washington, Seattle, WA 98195 USA

[9] Fred Hutchinson Canc Ctr, Seattle, WA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4516

引用

页数：1